Alogether, these results indicate that concurrent delivery of TA, IFNα, and IL-12 activates a genetic program in tumor-infiltrating T cells that may restore the therapeutic effect of a-PD1, providing proof-of-concept of a powerful therapeutic combination to treat cancer patients with an unmet clinical need. This evidence concerns the gene PDCD1 and neoplasm.